5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
about
Colitis-associated colon cancer: Is it in your genes?Ulcerative colitis-associated colorectal cancerSystematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitisThiopurines and inflammatory bowel disease: Current evidence and a historical perspectiveInflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity.Current management of inflammatory bowel disease and colorectal cancer.Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysisChemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis.Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?Colorectal Cancer in Inflammatory Bowel Disease: Epidemiology, Pathogenesis and SurveillanceDoes aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer.Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ.Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colonRole for epithelial dysregulation in early-onset colitis-associated colon cancer in Gi2-alpha-/- mice.Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Potential avenues for immunotherapy of colitis-associated neoplasia.Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer.Has the risk of colorectal cancer in inflammatory bowel disease decreased?The role of mucosal healing in the treatment of patients with inflammatory bowel diseaseThe potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.Colon cancer screening and surveillance in inflammatory bowel disease.Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.The long journey of salicylates in ulcerative colitis: The past and the future.Chemoprevention of colorectal cancer in inflammatory bowel disease.Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study.Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study.Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis.Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new?
P2860
Q26778018-0D121B54-38CE-4854-8ECE-D70607C441DEQ26822499-4DEA51AD-AF71-4FE8-BA7C-4340546FF559Q27011853-38C5A19D-B708-41CE-BE99-5B5F18A029BFQ28079644-D2F7698B-B4C5-4F4E-AC39-A66D4CF837D4Q30651444-029A3D6F-9623-4DA4-B2FC-05AC9082B54FQ33509847-6516BD9A-CD76-4267-BE92-2CC0D3884228Q34192660-6F2D31D2-2AFA-4CCE-8A0B-5590C7F1EF79Q34663857-21AD42C9-082E-41C8-82FB-969B0B46AE52Q35142116-5DEDFE44-01A1-439D-B670-279D59AA0BEAQ35619921-4FFCFA20-9374-4F03-9C43-640D7B5CEFAAQ36144484-6029B0C7-A916-4C1E-BAE0-6210A6C6BE26Q36281579-D31B0BD7-1421-481C-846E-496E8B110AD0Q36747550-36B0DA11-FF4F-4EE7-B0A9-632275690BFCQ36827259-F67EB4C2-3125-4EE8-BB81-FA51237B029FQ37018514-34403DA5-F8AD-4936-9E9B-A28C7ECC2A4DQ37262181-F1E59985-1CD4-464B-BA55-A0EC54166EF9Q37305789-F3BA1386-5D42-4719-BE3C-8758DF74DF1FQ37312057-4222C665-691C-4C0B-BE9A-3C9A59A383E7Q37393339-97631B86-AF3B-4DD8-8956-B97BCA4B4916Q37806620-3731415B-0387-4397-AA14-33145DA05058Q37814549-497B2870-2D16-4228-B901-22FE7E590354Q37892884-60D59A64-B495-4FEE-8866-5191E322414BQ38003476-19D25006-A700-48AD-9E3D-6F018C143B56Q38049779-BE89004C-BCA8-431E-B241-4B812E3AC11CQ38064743-46C1FB81-07D1-4D4C-9784-23B9BE6D922EQ38105801-80488828-6FFE-4AEC-AA01-2E7751133B25Q38134308-2A69CAE8-04AC-4870-B7CF-AE1887C25A8CQ38166711-F073CD85-428C-4EDB-A322-4CB903B89C65Q38176299-6E62495A-A46D-498C-B3EE-F55F617DE31CQ38224247-0689E4CD-2B9E-4E24-AA0B-BAF397200821Q38288038-8BB379CD-E9F1-45F1-9342-E029032FA910Q38571099-87A0FA51-8755-40DA-939D-900580666CE8Q38571119-A8487E64-53B9-4AB3-967E-DBBC27BC9D6BQ39016806-12CCD2CB-354C-434B-B3A4-C7EFAD9D2489Q39025709-8DA51445-BE83-48FF-97B4-813668B4AF26Q39162961-C451DAE4-1BA0-4F4F-816B-DE10AF66622FQ39705229-CEAB33D9-E6B9-4A99-A129-56BE8872E148Q39946903-E8E0EEEF-7085-470C-A3E5-E21179905FE3Q41287600-3E4317D7-3EDC-4B3E-BFEA-92FBA0F949F0Q42082755-02A88D72-E53E-4F42-8531-EE6B7DF6A534
P2860
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
5-Aminosalicylic acid therapy ...... th inflammatory bowel disease.
@en
5-Aminosalicylic acid therapy ...... th inflammatory bowel disease.
@nl
type
label
5-Aminosalicylic acid therapy ...... th inflammatory bowel disease.
@en
5-Aminosalicylic acid therapy ...... th inflammatory bowel disease.
@nl
prefLabel
5-Aminosalicylic acid therapy ...... th inflammatory bowel disease.
@en
5-Aminosalicylic acid therapy ...... th inflammatory bowel disease.
@nl
P2093
P2860
P921
P356
P1476
5-Aminosalicylic acid therapy ...... th inflammatory bowel disease.
@en
P2093
David T Rubin
Jonathan P Terdiman
Michael Steinbuch
Thomas A Ullman
William A Blumentals
P2860
P304
P356
10.1002/IBD.20074
P577
2007-04-01T00:00:00Z